SequelSEC

MEDIFAST INC MED

Miscellaneous Food Preparations & Kindred Products · CIK 0000910329 · Fiscal year ends 1231

Revenue
$385.79M
Fiscal year ended 2025-12-31
Operating income
-$14.21M
Fiscal year ended 2025-12-31
Free cash flow
$1.25M
Fiscal year ended 2025-12-31

MEDIFAST INC (MED) reported revenue of $385.79M and net income of -$18.67M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from MEDIFAST INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Miscellaneous Food Preparations & Kindred Products.

Income

MEDIFAST INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$385.79M$602.46M$1.07B$1.60B$1.53B$934.84M$713.67M$501.00M$301.56M$274.53M
Cost of revenue$110.60M$157.84M$296.20M$458.16M$398.49M$237.03M$176.81M$121.10M$73.75M$68.87M
Gross profit$275.19M$444.62M$775.85M$1.14B$1.13B$697.82M$536.86M$379.90M$227.81M$205.66M
Operating income-$14.21M$2.88M$126.40M$184.81M$216.24M$134.16M$91.04M$69.06M$39.63M$26.86M
Net income-$18.67M$2.09M$99.42M$143.57M$164.03M$102.86M$77.92M$55.79M$27.72M$17.84M
Research & development$4.30M$4.60M$4.60M$4.50M$4.40M$2.80M$2.70M$2.20M$1.50M$2.00M
Weighted-average diluted sharesshares 10.98Mshares 10.96Mshares 10.92Mshares 11.28Mshares 11.81Mshares 11.85Mshares 12.12Mshares 12.08Mshares 12.09Mshares 11.95M
Pretax income-$5.64M$3.79M$128.80M$184.06M$216.13M$134.26M$92.36M$70.55M$40.33M$27.12M
Income tax expense$13.03M$1.70M$29.38M$40.49M$52.10M$31.41M$14.45M$14.76M$12.60M$9.29M
Diluted EPS$-1.70$0.19$9.10$12.73$13.89$8.68$6.43$4.62$2.29$1.49
Selling, general & administrative$289.40M$441.74M$649.45M$955.61M$911.36M$563.66M$445.82M$310.84M$188.18M$178.80M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MEDIFAST INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$89.30M$90.93M$94.44M$87.69M$104.18M$163.72M$76.97M$81.36M$75.08M$52.44M
Total assets$247.97M$284.21M$309.91M$316.21M$398.33M$276.08M$194.65M$169.43M$145.93M$121.22M
Current assets$201.68M$214.40M$224.03M$222.78M$306.87M$234.31M$154.15M$145.52M$125.20M$101.30M
Total liabilities$49.05M$74.10M$108.43M$161.17M$195.85M$118.84M$89.82M$60.32M$37.35M$25.20M
Current liabilities$42.96M$64.16M$92.30M$140.89M$169.83M$111.35M$79.39M$60.32M$37.14M$24.42M
Total equity incl. NCI$198.92M$210.11M$201.48M$155.04M$202.47M$157.25M$104.83M$109.11M$106.56M$96.02M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$20.23M$42.42M$54.59M$118.86M$180.04M$53.39M$48.77M$38.89M$19.33M$18.31M
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$584.00K$1.44M$1.01M$576.00K$1.39M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

MEDIFAST INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$6.86M$24.48M$147.66M$194.57M$94.54M$145.20M$84.26M$60.82M$43.24M$25.35M
Capital expenditures$5.61M$7.45M$6.48M$16.68M$34.21M$5.89M$10.06M$4.94M$3.24M$2.88M
Investing cash flow-$7.93M-$26.52M-$61.05M-$11.41M-$29.06M-$1.28M-$6.33M-$1.20M-$3.16M-$2.04M
Financing cash flow-$564.00K-$1.52M-$79.79M-$199.58M-$125.13M-$57.14M-$82.32M-$53.33M-$17.36M-$12.92M
Net change in cash-$1.62M-$3.51M$6.75M-$16.49M-$59.54M$86.75M-$4.39M$6.29M$22.64M$10.40M
Stock-based compensation$7.64M$7.36M$8.19M$11.05M$9.90M$6.80M$4.52M$3.12M$4.27M$3.43M
Common dividends paid$195.00K$715.00K$73.02M$71.62M$63.86M$53.19M$35.40M$23.16M$15.39M$11.89M
Common share repurchases$0$0$3.60M$126.44M$56.00M$5.00M$33.11M$30.00MUnavailableUnavailable
Depreciation & amortization$14.24M$12.71M$13.11M$10.98M$6.81M$4.32M$4.62M$4.44M$4.21M$5.40M

Derived

MEDIFAST INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$1.25M$17.02M$141.17M$177.89M$60.34M$139.31M$74.20M$55.88M$40.00M$22.47M
Gross margin71.3%73.8%72.4%71.3%73.9%74.6%75.2%75.8%75.5%74.9%
Operating margin-3.7%0.5%11.8%11.6%14.2%14.4%12.8%13.8%13.1%9.8%
FCF margin0.3%2.8%13.2%11.1%4.0%14.9%10.4%11.2%13.3%8.2%
SBC / revenue2.0%1.2%0.8%0.7%0.6%0.7%0.6%0.6%1.4%1.2%
Current ratio4.69x3.34x2.43x1.58x1.81x2.10x1.94x2.41x3.37x4.15x
Revenue YoY growth-36.0%-43.8%-32.9%4.8%63.2%31.0%42.4%66.1%9.8%Unavailable
Net margin-4.8%0.3%9.3%9.0%10.7%11.0%10.9%11.1%9.2%6.5%
R&D / revenue1.1%0.8%0.4%0.3%0.3%0.3%0.4%0.4%0.5%0.7%
CapEx / revenue1.5%1.2%0.6%1.0%2.2%0.6%1.4%1.0%1.1%1.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable44.8%22.8%22.0%24.1%23.4%15.6%20.9%31.3%34.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MED in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-04-28View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2017-12-31

Difference 2018000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.